rifampin and Cholecystitis

Topics: Biliary Tract Diseases; Cholangitis; Cholecystitis; Clinical Trials as Topic; Humans; Rifampin; Staphylococcal Infections; Sulfobromophthalein; Urinary Tract Infections

A 54-year-old man presented with tuberculous spondylodiscitis associated to E. coli found in an intervertebral disc space needle biopsy. The enterobacteria came from a cholecystitis. The patient was cured by medical treatment, consisting in a non-surgical immobilization, antitubercular quadritherapy in association with a specific antibiotic treatment. No other case of spondylodiscitis caused by a mycobacterial coinfection pathogen has been reported so far.

Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal

Topics: Acute Disease; Child; Cholecystectomy; Cholecystitis; Combined Modality Therapy; Endocarditis, Bacterial; Floxacillin; Gallbladder; Gentamicins; Humans; Male; Ornidazole; Parenteral Nutrition, Total; Rifampin; Staphylococcal Infections; Ultrasonography

Topics: Adult; Aged; Asthma; Cholecystitis; Drug Tolerance; Ethambutol; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Peptic Ulcer; Rifampin; Tuberculosis, Pulmonary

Topics: Ampicillin; Anti-Bacterial Agents; Chenodeoxycholic Acid; Cholecystitis; Chronic Disease; Humans; Novobiocin; Parasympatholytics; Penicillins; Peptides; Rifampin

Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Bile; Cholecystitis; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Klebsiella; Male; Middle Aged; Pyelonephritis; Rifampin; Urinary Tract Infections

Topics: Adult; Aged; Animals; Chemical and Drug Induced Liver Injury; Cholangitis; Cholecystitis; Evaluation Studies as Topic; Humans; Liver; Liver Function Tests; Male; Middle Aged; Rifampin

Determination of the minimum inhibitory concentrations of rifamide necessary to inhibit organisms isolated from the biliary tract showed that the organisms were almost invariably sensitive to concentrations which are readily attainable in the biliary tract. Three cases of severe acute inflammation of the biliary tract were treated and this led to rapid clinical improvement. In 61 patients undergoing biliary surgery a random group was given rifamide 150 mg twice daily, beginning 24 hours before operation and continuing for three days afterwards. In the untreated group eight patients had infected bile at operation and five subsequently developed a wound infection. In the rifamide group three had infected bile at operation and only one developed a wound infection. A similar number of postoperative chest infections occurred in each group of patients. There is some evidence of reduction in length of hospital stay in the treated patients.

Topics: Acute Disease; Aged; Bile; Cholangitis; Cholecystitis; Cholelithiasis; Female; Gallbladder; Humans; Length of Stay; Male; Microbial Sensitivity Tests; Postoperative Complications; Respiratory Tract Infections; Rifampin; Surgical Wound Infection

Topics: Biliary Tract Diseases; Cholecystitis; Humans; Rifampin; Staphylococcal Infections

Topics: Aged; Bile Acids and Salts; Cholecystitis; Gallbladder Diseases; Humans; Middle Aged; Rifampin

Topics: Adult; Cholangitis; Cholecystitis; Female; Humans; Male; Middle Aged; Rifampin